Month: October 2017
-
RNA Meds Companies Partner on Human, Animal Vaccines
Synthetic Genomics Inc. and Arcturus Therapeutics Inc. are collaborating on longer-lasting and more robust RNA therapies and vaccines for humans and animals.
-
Artificial Beta Cells Shown to Produce Insulin as Needed
A biomedical engineering team developed artificial beta cells that in animal tests perform similar to natural cells in the pancreas to produce insulin as needed for controlling blood glucose levels.
-
Fox Foundation, 23andMe in Large-Scale Parkinson’s Study
The Michael J. Fox Foundation and personal genetics company 23andMe are recruiting a large group of individuals with and without Parkinson’s disease to provide a more complete picture of the disorder.
-
Novartis Acquires Nuclear Meds Developer in $3.9B Deal
Drug maker Novartis is purchasing a company that develops therapies and diagnostics using radio isotopes for neuroendocrine and other cancers.
-
Can You Set Up Shop In An Industry You Know Nothing About?
More often than not, you can learn all you need to know about any line of business.
-
Here’s What a Real Opioid Emergency Looks Like
Let’s be clear — the limited steps ordered by the president to reduce the numbers of people addicted to opioids don’t look anything like a response to an emergency.
-
Project to Develop Universal Flu Vaccine
An initiative joining academic, private, and national labs is designing a vaccine that covers all influenza strains, with clinical studies expected to begin early next year.
-
Validic Integrating Home Health Data for Clinical Care
An application is being developed for a health care system to integrate data from patients’ home medical devices into their electronic health records and clinical care plans.
-
Phone-Based Lupus Home Test Kit in Development
A home test kit using smartphone imaging is being created by biomedical engineers to detect kidney inflammation caused by lupus, an autoimmune disorder.
-
Blood-Thinning Drugs Linked with Lower Dementia Risk
People with irregular heart rhythms given anti-coagulation drugs to reduce their risk of stroke were also less likely to develop dementia than their counterparts not receiving blood-thinners.